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FIGURE 1. Meta-analysis of 2 trials comparing the effect in cardiac surgery on surgical site infection incidence of inserting a gentamicin implant before
wound closure versus no insertion of a gentamicin implant. CI, Confidence interval; OR, odds ratio.
Letters to the Editor3. We absolutely agree with Osawa
and Orii1 that in reality many
surgeons use antibiotics locally,
and that antibiotic use plays an
essential part in many different
methods to reduce sternal wound
infection.
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MEDIATORS OF THE
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RESPONSE
To the Editor:
We read with great interest the well-
documented work of Jouan and col-
leagues1 on gene polymorphism and
cytokine plasma levels as predictive
factors of complications after cardio-
pulmonary bypass (CPB). Previous
studies highlighted potential roles of
cytokines (eg, interleukin [IL]-6 and
-10) on post-CPB complications2,3
but without mechanistic explanations
of these elevated productions. The
interesting andwell-documented study
of Jouan and colleagues1 now gives
this mechanistic explanation. Genetic
testing of IL6-572G>C and IL10-
592C>Amight thus be a tool for iden-
tifying patients at the highest risk of
poor tolerance to the post-CPB inflam-
matory response. Another main inter-
est of this study is to bring some
doubts concerning the role (if any) of
other pro- or anti-inflammatory com-
pounds released during CPB, such as
angiogenic growth factors and lipidic
mediators, on post-CPB adverse
effects.4,5 It is clear that IL-6 and IL-
10 now can be considered as themaster
predictive control mediators of the
post-CPB inflammatory response.of Thoracic and Cardiovascular SurgeYves Denizot, PhDa
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j.jtcvs.2012.05.080Reply to the Editor:
We appreciate the comments of
Denizot and Nathan on our article
‘‘Gene Polymorphisms and Cytokine
Plasma Levels as Predictive Factors
of Complications After Cardiopulmo-
nary Bypass.’’1 However, even if wery c Volume 144, Number 3 743
